Insider · CIK 0001840110
L. Becker Hewes
Files at BPMC (Blueprint Medicines Corp), DMRA (Damora Therapeutics, Inc.). First filing Mar 7, 2025, latest Mar 7, 2025.
In brief
L. Becker Hewes files SEC Form 4 as officer at BPMC (Blueprint Medicines Corp), and also at DMRA (Damora Therapeutics, Inc.). Since Mar 7, 2025, L. Becker Hewes has reported 0 open-market buys worth $0 and 1 open-market sell worth $891k, the latest filed on Mar 7, 2025.
A track record needs three past buys with six months of prices behind them; L. Becker Hewes has 0, so none is measured yet.
The newest scored trade: sold $891k of BPMC on Mar 5, 2025, filed Mar 7, 2025, scored 38 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Blueprint Medicines Corp | $891k 10,095 shares | -25% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 6, 2025 | BPMC BLUEPRINT MEDICINES CORPORATION | 5,232 0.01% of outstanding | $459k | Mar 6, 2025 | $432k |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | DMRA Damora Therapeutics, Inc. | AGrant or award Common Stock | +264,629 | $0.00 | $0 | 264,629 | Jan 7, 2026 |
| Jan 5, 2026 | DMRA Damora Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +528,603 | $0.00 | $0 | 528,603 | Jan 7, 2026 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +21,353 | - | - | 51,772 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -50,165 | - | - | 1,607 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | UTender of shares Common Stock | -1,607 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,490 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,125 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,115 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -19,271 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | - | - | 0 | Jul 21, 2025 |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -4,863 | $88.80 | $432k | 35,651 | Mar 7, 2025 |
| Mar 6, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,691 | $87.42 | $235k | 32,960 | Mar 7, 2025 |
| Mar 6, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,541 | $87.98 | $224k | 30,419 | Mar 7, 2025 |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +11,000 | $0.00 | $0 | 40,514 | Mar 4, 2025 |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Stock Options (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Mar 4, 2025 |
Questions about L. Becker Hewes
Answered from the filings on this page, as of the latest one.
Is L. Becker Hewes buying or selling?
Not in the last 12 months. L. Becker Hewes's latest open-market trade on SEC Form 4 was sold $891k of BPMC on Mar 5, 2025.
How did L. Becker Hewes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and L. Becker Hewes has 0.
Where does L. Becker Hewes file Form 4?
L. Becker Hewes has filed Form 4 at BPMC (Blueprint Medicines Corp) as Chief Medical Officer; DMRA (Damora Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.